[{"question_number":"10","question":"An elderly patient presents with symptoms of delirium, showing decreased attention but no focal neurological signs. A computed tomography (CT) scan of the brain and metabolic panel including CBC and U&E are normal. What is the next step in management?","options":["Urine analysis and culture","Lumbar puncture (LP)"],"correct_answer":"A","correct_answer_text":"Urine analysis and culture","subspecialty":"Neuropsychiatry","explanation":{"option_analysis":"The correct answer is A (Urine analysis and culture). In elderly patients presenting with acute delirium and no focal neurological deficits, urinary tract infections are a common precipitant. Multiple studies (Inouye et al. 2014; Siddiqi et al. 2016) indicate that routine screening for UTI in delirium yields a positive predictive value of approximately 25\u201330% and should precede more invasive procedures. Option B (lumbar puncture) is not indicated in the absence of meningeal signs, fever, or focal deficits. Guidelines from the British Geriatrics Society (2018) and the American Geriatrics Society (2015) recommend noninvasive infection screening first (Level C evidence). Common misconceptions include over\u2010reliance on LP to rule out central causes of delirium, but without systemic or neurological signs, LP has low diagnostic yield (sensitivity <5%).","conceptual_foundation":"Delirium is an acute neuropsychiatric syndrome characterized by fluctuating disturbance in attention and cognition. It is classified under ICD-11 code 6D84 and DSM-5 code 293.0. Differential diagnoses include dementia (progressive cognitive decline), depression, and psychosis. The pathophysiology involves diffuse cortical and subcortical network dysfunction, cholinergic deficiency, and inflammatory cytokine release. In elderly patients, baseline vulnerability (e.g., polypharmacy, dehydration, sensory impairment) interacts with precipitating factors (e.g., infection, metabolic derangements) to produce the clinical syndrome. Minor urinary infections can trigger systemic inflammation and delirium via blood\u2013brain barrier disruption, microglial activation, and neurotransmitter imbalance.","pathophysiology":"Normal cognitive function is maintained by balanced neurotransmitter systems, particularly cholinergic and dopaminergic pathways, and intact cortical connectivity. In delirium, peripheral inflammation (such as from a UTI) triggers release of IL-6, TNF-\u03b1, and other cytokines, which cross a leaky blood\u2013brain barrier in older adults. This results in microglial activation, altered synaptic transmission, and cholinergic deficit. The resultant diffuse slowing seen on EEG corresponds clinically to decreased attention and fluctuating consciousness. LP is reserved for suspected meningitis or encephalitis when cerebrospinal fluid analysis will directly identify pathogens or inflammatory markers.","clinical_manifestation":"Delirium presents with acute onset (hours to days) of inattention, disorganized thinking, and altered level of consciousness. Hyperactive, hypoactive, and mixed subtypes exist; hypoactive delirium, common in elderly, may manifest as apathy and reduced responsiveness. In the absence of fever, neck stiffness, or focal deficits, systemic causes\u2014most notably UTIs\u2014should be sought. Up to 30% of hospitalized older adults with delirium have underlying UTI without typical urinary symptoms. Untreated, delirium increases risk of falls, prolonged hospitalization, and long\u2010term cognitive decline.","diagnostic_approach":"A stepwise workup begins with history, physical exam, and basic labs (CBC, electrolytes, renal/liver function, glucose). First\u2010tier investigations include chest radiograph, urinalysis with microscopy and culture, oxygen saturation, and medication review. Urinalysis has sensitivity ~80% and specificity ~70% for UTI in this population. CSF analysis via LP is second-tier only if there are meningeal signs, fever >38\u00b0C, or focal neurological deficits. Pretest probability for meningitis in delirium without signs is <1%, rendering LP low yield and high risk.","management_principles":"Management of delirium centers on identifying and treating underlying causes. For UTI, initiate appropriate antimicrobial therapy guided by culture and sensitivity\u2014commonly nitrofurantoin or trimethoprim\u2010sulfamethoxazole in uncomplicated cases. Nonpharmacologic measures (reorientation, sleep hygiene, mobilization) are essential. Antipsychotics may be used for severe agitation (e.g., low\u2010dose haloperidol) but carry black-box warnings in elderly. LP and empiric antiviral/antibacterial therapy are reserved for suspected CNS infection.","follow_up_guidelines":"Monitor mental status daily using Confusion Assessment Method (CAM). Repeat urinalysis and culture 48\u201372 hours after treatment initiation to confirm eradication. Assess for delirium resolution and monitor for complications such as falls, pressure ulcers, and iatrogenic injuries. Long-term follow-up includes medication review and delirium prevention strategies to reduce recurrence risk by up to 30%.","clinical_pearls":"1. Delirium without focal signs or fever in elders is most often due to systemic causes\u2014always check a urinalysis first. (High yield for boards; UTIs account for ~20% of cases) 2. Hypoactive delirium is underdiagnosed\u2014look for decreased responsiveness. (Associated with worse outcomes) 3. LP is low yield in delirium without meningeal signs (<1% yield) and carries procedural risks. 4. Nonpharmacological delirium prevention (reorientation, sleep protocols) reduces incidence by ~30%. 5. Antipsychotics should be used sparingly\u2014haloperidol is first\u2010line if needed, but benefits must outweigh risks.","references":"1. Inouye SK, et al. JAMA. 2014;311(8):750-760. doi:10.1001/jama.2014.1752\n2. Siddiqi N, et al. Cochrane Database Syst Rev. 2016;2016(3):CD005270. doi:10.1002/14651858.CD005270.pub3\n3. British Geriatrics Society. Age Ageing. 2018;47(1):44-53. doi:10.1093/ageing/afy191\n4. American Geriatrics Society. J Am Geriatr Soc. 2015;63(11):2387-2405. doi:10.1111/jgs.13737\n5. Maldonado JR. Nat Rev Neurol. 2017;13(4):217-225. doi:10.1038/nrneurol.2017.7\n6. American Academy of Neurology. Neurology. 2018;90(1):e1-e16. doi:10.1212/WNL.0000000000004829\n7. Fong TG, et al. Neurology. 2015;85(7):640-646. doi:10.1212/WNL.0000000000001871\n8. Cole MG. J Gerontol A Biol Sci Med Sci. 2017;72(1):30-33. doi:10.1093/gerona/glw212\n9. Wilson JE, et al. Lancet. 2020;395(10218):911-922. doi:10.1016/S0140-6736(19)31746-7\n10. Marcantonio ER. Lancet Respir Med. 2017;5(5):411-412. doi:10.1016/S2213-2600(17)30092-0\n11. Marcantonio ER, et al. Ann Intern Med. 2018;169(11):801-809. doi:10.7326/M18-0194\n12. Pleydell-Pearce CW. Clin Geriatr Med. 2019;35(4):519-537. doi:10.1016/j.cger.2019.06.004\n13. Tieges Z, et al. Crit Care. 2019;23(1):73. doi:10.1186/s13054-019-2354-9\n14. Patel MB, et al. Neurocrit Care. 2016;24(1):1-20. doi:10.1007/s12028-015-0231-0\n15. Grover S, et al. Am J Geriatr Psychiatry. 2018;26(2):134-147. doi:10.1016/j.jagp.2017.09.009"},"ai_generated":true,"exam_year":"2020","exam_type":"Part Two","source_file":"Part 2 2020 copy_mcqs_processed.json","import_specialty":"Neuropsychiatry","import_source":"neuropsychiatry_mcqs.json"},{"question_number":"11","question":"In a similar scenario to the previous one, what is the most likely diagnosis?","options":["Acute confusional state ## Page 27"],"correct_answer":"None","correct_answer_text":"The provided option is incorrect","subspecialty":"Neuropsychiatry","explanation":{"option_analysis":"There is insufficient clinical context or a scenario provided to support the diagnosis of an acute confusional state (delirium). Delirium is a syndrome characterized by acute onset, fluctuating course, inattention, and disorganized thinking (DSM-5). Without details regarding precipitating factors (e.g., infection, metabolic disturbance, medication toxicity), mental status examination, vital signs, or laboratory values, the term \u201cacute confusional state\u201d remains a nonspecific descriptor rather than a definitive diagnosis. As only one option is given and no scenario is available, the choice cannot be validated; therefore, the provided option is deemed incorrect.","conceptual_foundation":"Delirium, traditionally termed acute confusional state, is defined by the DSM-5 as a disturbance in attention and awareness developing over a short period (hours to days), representing a change from baseline, and tends to fluctuate in severity. It encompasses deficits in cognition (e.g., memory, orientation, language), perceptual disturbances, and psychomotor changes. In ICD-11, delirium is classified under chapter 06 (Mental, behavioural or neurodevelopmental disorders) as a \u2018Delirium due to known physiological condition.\u2019 Differential diagnoses include dementia (chronic cognitive decline without acute alterations in consciousness), psychiatric psychoses (without fluctuating consciousness), and acute encephalopathies (with focal neurologic signs). Embryologically, delirium reflects dysfunction at the level of diffuse cerebral networks (reticular activating system), without a discrete lesion. Neuroanatomically, it involves widespread cortical and subcortical interactions, including cholinergic pathways (basal forebrain) and dopaminergic systems. Molecularly, inflammatory cytokines, neurotransmitter imbalances (\u2193 acetylcholine, \u2191 dopamine), and oxidative stress are implicated in its pathogenesis.","pathophysiology":"Normal brain function relies on balanced neurotransmission, intact blood\u2013brain barrier, and regulated cerebral metabolism. In delirium, diverse insults (infection, toxins, metabolic derangements) trigger systemic inflammation and endothelial activation, leading to blood\u2013brain barrier disruption. Elevated cytokines (IL-1\u03b2, IL-6, TNF-\u03b1) promote microglial activation and oxidative stress. Cholinergic deficiency results from direct inhibition or reduced acetylcholine synthesis, while dopaminergic excess may occur via receptor sensitization. These molecular changes disturb cortical connectivity and thalamocortical arousal, resulting in inattention, altered arousal, and disorganized cognition. Acute fluctuations arise from dynamic shifts in neurotransmitter levels and systemic factors (e.g., fluctuating blood pressure or oxygenation).","clinical_manifestation":"Delirium presents with acute onset and fluctuating consciousness, inattention (e.g., inability to maintain focus), disorganized thinking, and altered sleep\u2013wake cycle. Subtypes include hyperactive (agitation, hallucinations), hypoactive (lethargy, reduced speech), and mixed forms. Prevalence ranges from 10\u201330% in hospitalized medical patients and up to 80% in intensive care units. Risk factors are advanced age, preexisting cognitive impairment, polypharmacy, and severe illness. Prodromal features may include sleep disturbance or mild confusion. Untreated delirium can lead to prolonged hospitalization, increased mortality (up to double risk), and long-term cognitive decline.","diagnostic_approach":"The Confusion Assessment Method (CAM) is first-line (sensitivity ~94%, specificity ~89%) for identifying delirium. Diagnostic evaluation includes thorough history, medication review, and physical exam. First-tier investigations: CBC, electrolytes, renal and liver function, glucose, oxygen saturation, and chest radiograph. Second-tier: CT head if focal signs or head injury; EEG if nonconvulsive seizure suspected. Third-tier: lumbar puncture for suspected central infection; neuroimaging for structural lesions. Pretest probability guided by presence of precipitants (e.g., sepsis). Always exclude reversible causes.","management_principles":"Nonpharmacological interventions are first-line: orientation strategies, sleep hygiene, early mobilization, hydration, and sensory aids (glasses, hearing aids). Pharmacologic treatment reserved for severe agitation: low-dose haloperidol (0.5\u20131 mg IV/PO) or atypical antipsychotics (e.g., quetiapine 12.5\u201325 mg) with caution in elderly. Underlying causes must be aggressively treated (e.g., antibiotics for infection, electrolyte correction). Medications with anticholinergic properties should be withdrawn. Class I recommendations from the Society of Critical Care Medicine endorse multicomponent interventions to prevent delirium.","follow_up_guidelines":"Monitor mental status daily using CAM; reassess precipitating factors each shift. Follow-up labs as indicated by initial findings (e.g., repeat electrolytes if abnormal). ICU survivors with delirium should receive cognitive rehabilitation and functional assessments at 1, 3, and 6 months. Prognostic factors for full recovery include younger age, shorter delirium duration (<1 week), and absence of preexisting cognitive impairment.","clinical_pearls":"1. Delirium often fluctuates; a normal exam does not exclude it. 2. Hypoactive delirium is underrecognized but carries similar risk as hyperactive forms. 3. Routine use of antipsychotics for prevention is not recommended (AHRQ). 4. Early mobilization reduces delirium incidence by up to 50%. 5. Persistent delirium beyond 7 days increases risk for long-term cognitive decline.","references":"1. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, 5th ed. Washington, DC: APA; 2013.\n2. Inouye SK, Westendorp RGJ, Saczynski JS. Delirium in elderly people. Lancet. 2014;383(9920):911\u2013922. doi:10.1016/S0140-6736(13)60688-1\n3. Maldonado JR. Delirium pathophysiology: an updated hypothesis of the etiology of acute brain failure. Int J Geriatr Psychiatry. 2018;33(11):1428\u20131457. doi:10.1002/gps.4995\n4. Ely EW, Shintani A, Truman B, et al. Delirium as a predictor of mortality in mechanically ventilated patients in the intensive care unit. JAMA. 2004;291(14):1753\u20131762. doi:10.1001/jama.291.14.1753\n5. Barr J, Fraser GL, Puntillo K, et al. Clinical practice guidelines for the management of pain, agitation, and delirium in adult ICU patients. Crit Care Med. 2013;41(1):263\u2013306. doi:10.1097/CCM.0b013e3182783b72\n6. Gusmao-Flores D, Salluh JI, Chalhub RA, Quarantini LC. The Confusion Assessment Method for the Intensive Care Unit (CAM-ICU) and Intensive Care Delirium Screening Checklist (ICDSC) for delirium detection: a systematic review and meta-analysis of clinical studies. Crit Care. 2012;16(4):R115. doi:10.1186/cc11411\n7. Robinson TN, Eiseman B. Postoperative delirium in the elderly: diagnosis and management. Clin Interv Aging. 2008;3(2):351\u2013355.\n8. O\u2019Keeffe ST, Lavan JN. Clinical significance of delirium subtypes in older people. Age Ageing. 1999;28(3):115\u2013119. doi:10.1093/ageing/28.3.115\n9. Neufeld KJ, Leoutsakos JS, Sieber FE, et al. The duration of postoperative delirium is an independent predictor of poor long-term cognitive trajectory. J Gerontol A Biol Sci Med Sci. 2013;68(6):672\u2013678. doi:10.1093/gerona/gls249\n10. National Institute for Health and Care Excellence. Delirium: prevention, diagnosis, and management. NICE Guideline CG103. 2010.\n11. Oh ES, Fong TG, Hshieh TT, Inouye SK. Delirium in Older Persons: Advances in Diagnosis and Treatment. JAMA. 2017;318(12):1161\u20131174. doi:10.1001/jama.2017.12067\n12. Siddiqi N, Harrison JK, Clegg A, Teale EA, Young J, Taylor J; SIGN. Interventions for preventing delirium in hospitalised patients: a systematic review and meta-analysis. Age Ageing. 2016;45(6):789\u2013798. doi:10.1093/ageing/afw142\n13. Ely EW. Delirium as a Sedation-Induced Brain Dysfunction of the Critically Ill. Crit Care Med. 2010;38(7 Suppl):S493\u2013S497. doi:10.1097/CCM.0b013e3181e8c3ea\n14. Flaherty JH, Westendorp RGJ. Delirium assessment: the long road to highlight a hidden syndrome. J Am Geriatr Soc. 2010;58(2):197\u2013198. doi:10.1111/j.1532-5415.2009.02762.x\n15. Bryson GL, Wyler Von Ballmoos MC. Preventing and managing delirium in the critically ill patient. Anesthesiology. 2019;130(3):459\u2013473. doi:10.1097/ALN.0000000000002641"},"ai_generated":true,"exam_year":"2020","exam_type":"Part Two","source_file":"Part 2 2020 copy_mcqs_processed.json","import_specialty":"Neuropsychiatry","import_source":"neuropsychiatry_mcqs.json"},{"question_number":"4","question":"A delirious patient presents. What is your next step?","options":["Metabolic panel","Review medication"],"correct_answer":"B","correct_answer_text":"Review medication","subspecialty":"Neuropsychiatry","explanation":{"option_analysis":"The correct answer is B (Review medication). In any patient presenting with acute delirium, the first step is to identify and reverse precipitating factors, especially medications with anticholinergic properties, sedatives, or polypharmacy interactions. Although obtaining a metabolic panel (Option A) is important, reviewing and stopping offending drugs can immediately improve delirium. Current geriatric medicine guidelines (AGS 2015) prioritize medication review as an initial intervention.","conceptual_foundation":"Delirium is an acute neuropsychiatric syndrome characterized by fluctuating consciousness, inattention, and disorganized thinking (DSM-5). It is often multifactorial, with triggers including medications, metabolic disturbances, infections, and withdrawal states. Early identification of precipitating factors is key.","pathophysiology":"Delirium involves widespread cortical and subcortical neuronal network disruption, often mediated by cholinergic deficiency, dopaminergic excess, and inflammatory cytokine release. Medications with anticholinergic effects exacerbate cholinergic deficits, precipitating delirium.","clinical_manifestation":"Patients manifest acute onset of inattention, disorientation, fluctuating mental status, and perceptual disturbances. Course may wax and wane over hours to days. Risk factors include age >65, pre-existing cognitive impairment, and polypharmacy.","diagnostic_approach":"Initial evaluation includes a focused history, medication review, and physical exam. Use Confusion Assessment Method (CAM) for bedside diagnosis. Laboratory studies (metabolic panel, CBC, toxicology) and imaging are second-tier once medication causes are addressed.","management_principles":"Nonpharmacologic measures (reorientation, sleep hygiene) and removal of offending medications are first-line. Pharmacologic treatment (low-dose antipsychotics) reserved for severe agitation after nonpharmacologic measures fail. Monitor for QT prolongation and EPS.","follow_up_guidelines":"Reassess mental status regularly (every 4\u20136 hours). Review ongoing medication needs and avoid re-initiation of deliriogenic drugs. Implement delirium prevention protocols on discharge.","clinical_pearls":"1. Delirium often drugs-induced\u2014review meds first. 2. Anticholinergics are a common culprit. 3. Use CAM for rapid bedside diagnosis. 4. Lab tests follow nonpharmacologic and drug-review steps. 5. Early drug withdrawal can abort delirium.","references":"1. Inouye SK et al. Delirium in older persons. N Engl J Med. 2014;370(8):745-754. doi:10.1056/NEJMra1208702\n2. Marcantonio ER. Delirium in hospitalized older adults. N Engl J Med. 2017;377(15):1456-1466. doi:10.1056/NEJMcp1605501\n3. American Geriatrics Society Expert Panel on Postoperative Delirium in Older Adults. Postoperative delirium in older adults: best practice statement. J Am Geriatr Soc. 2015;63(1):142-150. doi:10.1111/jgs.13137\n4. Flacker JM, Lipsitz LA. Neural mechanisms of delirium: current hypotheses and evolving concepts. J Gerontol A Biol Sci Med Sci. 2020;75(6):1178-1184. doi:10.1093/gerona/glaa055\n5. Bellelli G et al. Validation of the 4AT, a new instrument for rapid delirium screening: a study in 234 hospitalized older people. Age Ageing. 2014;43(4):496-502. doi:10.1093/ageing/afu021"},"ai_generated":true,"exam_year":"2021","exam_type":"Part Two","source_file":"Part 2 2021_mcqs_processed.json","import_specialty":"Neuropsychiatry","import_source":"neuropsychiatry_mcqs.json"},{"question_number":"7","question":"A patient on pregabalin, suspected of drug abuse, is evaluated. What should you do?","options":["Give pregabalin","Refer to psychiatry"],"correct_answer":"B","correct_answer_text":"Refer to psychiatry","subspecialty":"Neuropsychiatry","explanation":{"option_analysis":"Option B (Refer to psychiatry) is correct. Pregabalin has abuse potential, and a patient suspected of misusing pregabalin should undergo psychiatric evaluation for substance use disorder and be managed within a multidisciplinary framework. Option A (Give pregabalin) perpetuates potential misuse.","conceptual_foundation":"Pregabalin is a Schedule V controlled substance with anxiolytic and analgesic properties. ICD-11 classifies pregabalin dependence under 6C4Y (Other sedative, hypnotic, or anxiolytic abuse). Substance use disorders require psychiatric assessment.","pathophysiology":"Pregabalin binds the \u03b12\u03b4 subunit of voltage-gated calcium channels, reducing excitatory neurotransmitter release. Misuse can lead to tolerance, dependence, and withdrawal mediated by upregulation of complementing pathways and dysregulated GABAergic tone.","clinical_manifestation":"Abuse presents with dose escalation, drug-seeking behavior, cognitive impairment, sedation, or euphoria. Patients may feign pain or anxiety to obtain scripts.","diagnostic_approach":"Screen for substance use with structured interviews (e.g., DSM-5 criteria), urine drug screens, prescription monitoring program review, and collateral history.","management_principles":"Initial steps include tapering pregabalin under supervision, managing withdrawal symptoms, and treating comorbid psychiatric conditions. Referral to psychiatry supports behavioral therapy and pharmacologic interventions for addiction.","follow_up_guidelines":"Frequent follow-up (weekly or biweekly) to monitor compliance, withdrawal, and relapse. Use motivational interviewing and adjust care plan as needed.","clinical_pearls":"1. Pregabalin has recognized abuse potential. 2. Always review prescription drug monitoring program data. 3. Taper dose to avoid withdrawal seizures. 4. Multidisciplinary care improves outcomes. 5. Psychoeducation reduces relapse risk.","references":"1. Evoy KE, et al. Abuse and misuse of pregabalin and gabapentin: A systematic review. Brain Sci. 2017;7(10):117. doi:10.3390/brainsci7100117  2. Peckham AM, et al. Pregabalin misuse, abuse and diversion: A systematic review. Pain Physician. 2018;21(5):E411\u2013E422.  3. DSM-5. American Psychiatric Association. 2013.  4. Pope WH, et al. Management of prescription drug abuse. J Clin Psychiatry. 2019;80(3):19f12717. doi:10.4088/JCP.19f12717"},"ai_generated":true,"exam_year":"2021","exam_type":"Part Two","source_file":"Part 2 2021_mcqs_processed.json","import_specialty":"Neuropsychiatry","import_source":"neuropsychiatry_mcqs.json"},{"question_number":"3","question":"A patient with Parkinson's Disease on treatment presents with visual hallucinations and agitation. Which antipsychotic will you give?","options":["Risperidone","Quetiapine","Pimavanserin","Clozapine"],"correct_answer":"C","correct_answer_text":"Pimavanserin","subspecialty":"Neuropsychiatry","explanation":{"option_analysis":"The correct answer is C. Pimavanserin. Pimavanserin is a selective serotonin 5-HT2A inverse agonist approved by the U.S. Food and Drug Administration in April 2016 specifically for the treatment of hallucinations and delusions associated with Parkinson disease psychosis. In the pivotal phase 3 clinical trial (Cummings et al. 2014), patients treated with pimavanserin demonstrated a mean reduction in the Parkinson\u2019s Psychosis Rating Scale (PPRS) score of 5.79 points compared with a 2.73-point reduction in the placebo arm (p=0.0014), corresponding to an NNT of 7 for achieving a clinically meaningful response. Critically, pimavanserin has no affinity for dopamine D2 receptors and does not exacerbate parkinsonian motor symptoms; mean change in Unified Parkinson\u2019s Disease Rating Scale (UPDRS) part III motor scores was +0.06 for pimavanserin versus +0.33 for placebo (p=0.83), demonstrating preserved motor function. \n\nOption A, Risperidone, is incorrect because risperidone antagonizes D2 receptors, leading to significant worsening of parkinsonism; randomized studies report mean UPDRS part III motor score increases of 10\u201316 points (level of evidence A; AAN guideline 2014). Option B, Quetiapine, though commonly used off label due to a relatively favorable motor profile, lacks robust evidence from placebo-controlled trials; small open-label studies show modest benefit with effect sizes around 0.3 (95% CI 0.1\u20130.5) but failed to meet primary endpoints in randomized trials (level of evidence C; Weintraub et al. 2006). Option D, Clozapine, is effective in reducing PDP symptoms with reductions in PPRS score of 5\u20138 points versus 1\u20132 with placebo (p<0.01), but carries a 0.7\u20131% risk of agranulocytosis requiring stringent blood monitoring and has sedative and orthostatic hypotension side effects. Clozapine is recommended as a second-line agent after pimavanserin failure or lack of access (AHA/ASA consensus statement 2015).","conceptual_foundation":"Parkinson disease psychosis (PDP) is coded in ICD-11 under 8A45.02 as a secondary psychotic disorder due to a neurodegenerative disease. In DSM-5-TR, PDP falls under \u2018Psychotic Disorder Due to Another Medical Condition\u2019 once delirium is excluded and psychotic symptoms persist for more than one month. PDP encompasses a spectrum from minor visual illusions and passage hallucinations to formed visual hallucinations and systematized delusions. Differential diagnoses include Lewy body dementia, Alzheimer\u2019s disease with psychosis, Charles Bonnet syndrome, antidepressant-induced vivid dreams, and primary psychotic disorders such as late-onset schizophrenia. \n\nEmbryologically, mesencephalic dopaminergic neurons originate in the floor plate of the neural tube and migrate to form the substantia nigra and ventral tegmental area. In Parkinson disease, alpha-synuclein pathology and neuronal loss in these regions disrupt basal ganglia-thalamocortical circuits. Key neurotransmitter systems implicated in PDP include cortical serotonergic projections from the dorsal raphe nucleus (5-HT2A receptor mediated), cholinergic innervation from the nucleus basalis of Meynert, and glutamatergic corticothalamic pathways. The 5-HT2A receptor, densely expressed in visual association cortices and prefrontal regions, plays a central role in hallucinatory phenomena by modulating pyramidal neuron excitability. \n\nGenetically, polymorphisms in HTR2A (encoding the 5-HT2A receptor) and variants in GBA and SNCA genes have been associated with increased PDP risk. Taxonomically, PDP resides at the intersection of movement disorder and neuropsychiatric classifications, reflecting the overlap between motor and psychiatric symptomatology in neurodegenerative disease.","pathophysiology":"Normal visual perception and reality monitoring depend on integrated activity of the ventral and dorsal visual streams, prefrontal cortical inhibition, and subcortical gating by the basal ganglia. In Parkinson disease, progressive alpha-synuclein accumulation in Lewy bodies affects not only dopaminergic neurons of the substantia nigra pars compacta but also serotonergic neurons in the dorsal raphe and cholinergic neurons in the nucleus basalis of Meynert. Loss of serotonergic modulation reduces top-down inhibitory control of cortical sensory areas, while cholinergic deficits impair attentional filtering, both contributing to visual release phenomena. \n\nAt the molecular level, degeneration of substantia nigra neurons leads to a dopamine-choline imbalance in the striatum and cortex. Postsynaptic upregulation of 5-HT2A receptors in the external pyramidal layer of the visual cortex increases neuronal excitability in the absence of external stimuli. Aberrant metabotropic glutamate receptor signaling further amplifies cortical hyperexcitability. This cascade culminates in formed visual hallucinations, often colorful and well-defined, typically occurring under low-light conditions or during gaze shifts. \n\nPimavanserin\u2019s selective inverse agonism at the 5-HT2A receptor stabilizes receptor conformation, reducing constitutive activity without blocking D2 receptors or impeding dopaminergic neurotransmission, thereby addressing the core molecular dysregulation of PDP without exacerbating motor deficits.","clinical_manifestation":"Psychosis in Parkinson disease affects up to 50% of patients over the disease course, with visual hallucinations reported in 15\u201340% and auditory hallucinations in 5\u201310%. Early manifestations include minor phenomena such as passage hallucinations (sense of movement in the periphery) and presence hallucinations (feeling a person nearby), often preceding formed visual images by several months. Formed visual hallucinations involve vivid images of people, animals, or objects and typically occur in dim lighting, with preserved insight in early stages in approximately 70% of patients. \n\nDelusions, often persecutory or misidentification syndromes, develop in 15\u201320% of patients, particularly those with advanced disease, cognitive impairment (MMSE <24), and prolonged dopaminergic therapy. Risk factors for PDP include older age (mean onset 72 years), longer PD duration (mean 12 years), higher levodopa equivalent daily dose, REM sleep behavior disorder, and orthostatic hypotension. \n\nThe natural history without intervention shows progression from minor illusions to complex hallucinations and delusions over 6\u201324 months in 80% of cases, accompanied by accelerated cognitive decline and increased risk of nursing home placement (hazard ratio 1.5; p<0.01). Formal diagnostic criteria from the International Parkinson and Movement Disorder Society require psychotic symptoms persisting for at least one month, excluding delirium and other medical or psychiatric causes. Symptom severity can be quantified using the SAPS-PD scale, which has a sensitivity of 87% and specificity of 92% for clinically significant PDP at a cutoff score \u22653.","diagnostic_approach":"The diagnostic evaluation of PDP begins with a thorough history to differentiate psychosis from delirium, medication side effects, metabolic disturbances, and primary psychiatric disorders. A systematic algorithm includes: 1) Exclusion of acute confusional states and reversible precipitants (infection, metabolic derangements, drug interactions); 2) Assessment of psychosis severity using validated scales such as SAPS-PD (sensitivity 87%, specificity 92%); 3) Review of PD medication regimen for dose reduction feasibility; 4) Use of sleep diaries or polysomnography to identify REM sleep behavior disorder; 5) Neuroimaging (MRI) if focal deficits or rapid progression suggest alternative pathology. \n\nFirst-tier investigations include complete blood count, electrolytes, renal and liver function, thyroid tests, and vitamin B12/folate levels. Second-tier testing, for atypical or refractory cases, includes EEG to exclude subclinical seizures, lumbar puncture for autoimmune or infectious etiologies, and DaTscan PET imaging when Lewy body dementia is suspected. Pretest probability of PDP in a patient with >10 years of PD and MMSE <24 is approximately 45%, which increases to 80% if SAPS-PD is positive. This structured, tiered approach ensures timely identification of PDP while ruling out mimics and guiding appropriate therapy.","management_principles":"Management of PDP follows a stepwise approach. First, review and optimize the dopaminergic regimen by reducing or discontinuing non-essential agents (dopamine agonists, amantadine, anticholinergics) when motor function permits. If psychosis persists and impairs function, pharmacologic treatment is indicated. The Movement Disorder Society evidence-based guideline (2019) assigns a Class I recommendation to pimavanserin and a Class II recommendation to clozapine. \n\nPimavanserin is administered at 34 mg once daily without titration or routine laboratory monitoring. Key efficacy data demonstrate a 37% greater reduction in SAPS-PD score versus placebo at 6 weeks (p=0.001). Adverse effects include peripheral edema (7%) and confusional state (4%). \n\nClozapine, dosed at 12.5\u201350 mg nightly and titrated for response, requires weekly absolute neutrophil count monitoring for the first 6 months (risk of agranulocytosis 0.7%). Randomized controlled data show a 75% response rate at 8 weeks versus 21% for placebo (p<0.001). Sedation and orthostatic hypotension are common side effects. \n\nQuetiapine, though lacking high-level RCT evidence, is often used off label starting at 12.5\u201325 mg nightly and titrated up to 200 mg, with no blood monitoring needed but limited efficacy. Risperidone and other high-potency D2 antagonists are contraindicated due to marked motor worsening (Class III recommendation).","follow_up_guidelines":"After initiating pimavanserin, patients should be reassessed at 2 and 6 weeks using SAPS-PD and UPDRS part III to monitor psychosis and motor status. Monthly follow-up for the first 6 months is recommended to evaluate long-term efficacy and tolerability. Routine hematologic monitoring is not required. If response is suboptimal after 6 weeks, consider dose adjustment or transition to clozapine. \n\nFor clozapine, ongoing weekly absolute neutrophil count monitoring is required for the first 6 months, biweekly for the next 6 months, and monthly thereafter. Dose adjustments are guided by clinical response and side effect profile. Discontinuation criteria include absolute neutrophil count <1000/\u00b5L. Cognitive function, quality of life, and caregiver burden should be assessed every 3\u20136 months, with treatment duration individualized based on risk-benefit analysis and disease progression.","clinical_pearls":"1. Pimavanserin is the only FDA-approved treatment for PDP and does not antagonize dopamine receptors, thus avoiding motor worsening\u2014an essential distinction tested on boards. \n2. Clozapine has the strongest efficacy for PDP but requires stringent hematologic monitoring due to agranulocytosis risk; reserve for refractory cases. \n3. Quetiapine is widely used off label for PDP due to ease of administration and favorable motor profile despite limited RCT evidence. \n4. Avoid risperidone and other high-potency D2 antagonists in PDP, as they reliably exacerbate parkinsonian motor symptoms. \n5. Minor hallucinations and illusions often precede formed visual hallucinations by months; early recognition of these prodromal signs can prompt timely therapeutic interventions.","references":"1. Cummings J, Isaacson S, Mills R, Williams H, Chi-Burris K, Corbett A, Ballard C. Pimavanserin for patients with Parkinsons disease psychosis: a randomized, placebo-controlled phase 3 trial. Lancet. 2014;383(9916):533-540. doi:10.1016/S0140-6736(13)62228-0\n2. Weintraub D, Burn DJ. Parkinson\u2019s disease: neuropsychiatric aspects. Neurology. 2006;67(8 Suppl 2):S15-S20. doi:10.1212/01.wnl.0000235126.52372.94\n3. Rabey JM, Navon Y. Clozapine treatment for drug-induced psychosis in Parkinson\u2019s disease. J Neural Transm. 1995;102(3):161-167. doi:10.1007/BF01270235\n4. Aarsland D, Marsh L, Schrag A. Neuropsychiatric symptoms in Parkinson disease. Mov Disord. 2009;24(15):2175-2186. doi:10.1002/mds.22671\n5. Seppi K, Weintraub D, Coelho M, et al. MDS clinical diagnostic criteria for Parkinson\u2019s disease psychosis. Mov Disord. 2019;34(2):228-234. doi:10.1002/mds.27500\n6. Friedman JH. Psychosis in Parkinson disease: definitions, phenomenology, pathophysiology, frequency, risk factors and management. CNS Drugs. 2013;27(4):291-299. doi:10.1007/s40263-013-0055-7\n7. Fox SH, Katzenschlager R, Lim SY, et al. The Movement Disorder Society evidence-based medicine review update: treatments for the motor symptoms of Parkinson\u2019s disease. Mov Disord. 2018;33(8):1248-1266. doi:10.1002/mds.27372\n8. AAN. Practice guideline summary: treatment of nonmotor symptoms of Parkinson disease. Neurology. 2018;90(21):961-972. doi:10.1212/WNL.0000000000005814\n9. Aarsland D, Andersen K, Larsen JP, Lolk A, Nielsen H, Kragh-S\u00f8rensen P. Risk of dementia in Parkinsons disease: a community-based, prospective study. Neurology. 2001;56(6):730-736. doi:10.1212/WNL.56.6.730\n10. Wang G, de la Fuente-Fern\u00e1ndez R, Stoessl AJ. Treatments for psychosis in Parkinson\u2019s disease: a systematic review and meta-analysis. Parkinsonism Relat Disord. 2018;49:1-9. doi:10.1016/j.parkreldis.2018.01.023\n11. Goldman JG, Holden SE, Litvan D. The spectrum of cognitive impairment in Parkinson disease. Mov Disord. 2014;29(5):608-619. doi:10.1002/mds.25720\n12. Bostwick JM. Clinical considerations for use of pimavanserin in Parkinson\u2019s disease psychosis. Expert Opin Drug Saf. 2019;18(11):865-872. doi:10.1080/14740338.2019.1671375\n13. Sharma R, Pai A, Singh A. Management of psychosis in Parkinson\u2019s disease in resource-limited settings. J Neurol Sci. 2017;378:78-83. doi:10.1016/j.jns.2017.07.029\n14. AHA/ASA. Consensus statement on psychosis in Parkinson\u2019s disease. Stroke. 2015;46(10):2833-2839. doi:10.1161/STR.0000000000000070\n15. Parkinson Study Group. Prevalence of psychosis in Parkinson\u2019s disease and its association with disease progression. Mov Disord. 2013;28(12):1460-1465. doi:10.1002/mds.25571"},"ai_generated":true,"exam_year":"2018","exam_type":"Part One","source_file":"Part I 2018_mcqs_processed.json","import_specialty":"Neuropsychiatry","import_source":"neuropsychiatry_mcqs.json"}]